📉 The Financial Deep Dive
Sai Life Sciences Limited has reported a robust financial performance for the quarter and nine months ended December 31, 2025, demonstrating significant year-on-year (YoY) growth across key metrics.
The Numbers:
- Consolidated Revenue for the quarter surged by 26.53% YoY to ₹5,564.64 million.
- Consolidated Profit After Tax (PAT) saw a dramatic increase of 86.39% YoY, reaching ₹1,003.75 million.
- This translated to a consolidated PAT margin of 18.04% for the quarter, an improvement from the prior year period (margin not explicitly calculable without prior year PAT/Revenue).
- Consolidated Diluted Earnings Per Share (EPS) grew substantially to ₹4.71, from ₹2.84 in the prior year period, marking a 65.85% YoY increase.
- Consolidated Revenue grew by 42.62% YoY to ₹15,903.53 million.
- Consolidated PAT witnessed an exceptional surge of 198.33% YoY to ₹2,446.74 million.
- The consolidated PAT margin for the nine months stood at 15.38%.
- Consolidated Diluted EPS more than doubled to ₹11.53, up from ₹4.31 YoY, a 167.52% increase.
Exceptional Item:
An exceptional item of loss amounting to ₹82.93 million was recognized in the current quarter and nine-month period. This loss is attributed to the assessment of financial implications arising from the enactment of new Labour Codes, specifically impacting gratuity and leave liabilities, and has been classified as a non-recurring event.
Employee Stock Options:
Separately, the Nomination and Remuneration Committee approved the grant of 205,000 employee stock options (ESOPs) under the existing management ESOP Scheme – 2018.
Auditor's Report:
The statutory auditors, M/s. Deloitte Haskins & Sells LLP, have reviewed the results and issued an unmodified conclusion for both standalone and consolidated financial statements, confirming no material misstatements were found during the limited review.
🚩 Risks & Outlook
Specific Risks:
- The recognized exceptional loss of ₹82.93 million, while deemed non-recurring, impacted the reported quarterly and nine-month PAT figures.
- The grant of 205,000 ESOPs could lead to future dilution of earnings per share.
- The long-term financial implications of the new Labour Codes on liabilities will require ongoing monitoring.
Investors will be keenly observing the sustainability of Sai Life Sciences' strong revenue and PAT growth trajectory in the upcoming quarters. The company's ability to manage costs and integrate new regulatory compliance, following the Labour Codes, will be crucial. The unmodified auditor's report provides a positive signal on financial reporting quality.